Drug Price Trends for CYCLOGYL

Average Pharmacy Cost for CYCLOGYL

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
CYCLOGYL 0.5% EYE DROPS	00065-0395-15	6.40467	ML	2026-07-22
CYCLOGYL 0.5% EYE DROPS	00065-0395-15	6.40467	ML	2026-06-17
CYCLOGYL 0.5% EYE DROPS	00065-0395-15	6.40667	ML	2026-05-20
CYCLOGYL 0.5% EYE DROPS	00065-0395-15	6.40667	ML	2026-04-22

Market Analysis and Price Projections for CYCLOGYL

Last updated: February 13, 2026

Overview

CYCLOGYL (cyclophosphamide) is an alkylating agent used primarily in the treatment of various cancers, including lymphoma, leukemia, and solid tumors. Its market landscape is influenced by increasing adoption rates in oncology, regulatory approvals, patent status, and competition from newer therapies. The drug's pricing and market growth are also affected by healthcare policies, reimbursement frameworks, and emerging biosimilars.

Market Size and Growth Trends

• Global Oncology Drug Market: Expected to reach $242 billion by 2026, growing at a CAGR of 7.2% (source: Transparency Market Research [1]).

• Cyclophosphamide Segment: Estimated to represent 3-4% of the total oncology market, translating to a value of approximately $7-10 billion in 2023.

• Key Drivers:

  • Increased prevalence of lymphoma and leukemia.
  • Expansion of indications in autoimmune diseases.
  • Rising approval for combination regimens in chemotherapy.

• Market Penetration:

  • Widely used in low-to-middle income countries due to affordability.
  • Usage in high-income countries declines in some regions owing to newer agents, but remains essential in specific indications.

Competitive Landscape

• Major Producers:

  • Baxter (Teva)
  • Pfizer
  • Hikma Pharmaceuticals
  • Biosimilars entering markets with lower-cost options.

• Biosimilar Impact:

  • Several biosimilars approved in Europe and emerging approvals in the U.S.
  • Forecasted to reduce prices by 20-30% over the next five years.

• Patent Status:

  • Original patents expired or are close to expiry in many regions.
  • Limited proprietary exclusivity constrains pricing power.

Pricing Dynamics

• Historical Prices:

  • IV cyclophosphamide: $50-$150 per vial (dependent on volume, region).
  • Oral formulations tend to be less expensive, approximately $10-$30 per dose.

• Market Price Trends:

  • Prices have decreased by roughly 15% over the past five years due to generic competition and biosource proliferation.

• Reimbursement Policies:

  • Reimbursement varies; in the U.S., Medicare and Medicaid significantly influence pricing.
  • In Europe, National Health Services negotiate prices, often resulting in lower costs.

Price Projections (2023-2030)

Year	Estimated Average Price (per vial/oral dose)	Notes
2023	$50 - $70	Current market with biosimilar competition
2025	$40 - $60	Increased biosimilar adoption
2030	$30 - $50	Further biosimilar penetration and price pressures

• Assumptions:
  • Continuation of biosimilar approvals and market penetration.
  • No significant patent extensions or new formulations delaying generics.
  • Healthcare funding remains relatively stable globally.

Regulatory and Policy Impact

• U.S.: The FDA recent approvals of biosimilars such as Truxima (rituximab biosimilar with implications for similar agents) may accelerate price reductions.
• Europe: Strong biosimilar adoption, further pressuring prices.
• Emerging Markets: Less price compression due to procurement policies and supply chain factors.

Key Risks Influencing Market and Price

• Slow biosimilar uptake in certain regions.
• Development of targeted therapies with better safety profiles.
• Regulatory hurdles delaying biosimilar entry.
• Shifts in treatment guidelines favoring newer agents.

---

Key Takeaways

• The global cyclophosphamide market is approximately $7-10 billion in 2023 and is growing modestly.
• Price declines of 20-30% are projected over five years due to biosimilar competition.
• The drug maintains vital importance in specific indications, with market dynamics heavily influenced by regulatory approvals and healthcare policies.
• Pricing will vary considerably by region, with high-income markets experiencing steeper declines due to biosimilar adoption.
• Future market growth relies on expanding indications and overcoming the competitive pressure from newer immunotherapies.

---

FAQs

1. What factors most influence CYCLOGYL's market size?
   The prevalence of cancers treated with cyclophosphamide, regulatory approvals, biosimilar competition, and healthcare reimbursement policies.

2. How will biosimilars impact drug prices?
   Biosimilars are expected to reduce prices by 20-30% over five years, especially in Europe and developed markets.

3. Are there new formulations or combination therapies affecting CYCLOGYL’s sales?
   Yes. Newer combination regimens and targeted therapies may diminish reliance on cyclophosphamide in some indications.

4. What regions will experience the fastest price declines?
   Europe and North America due to early biosimilar adoption and aggressive pricing strategies.

5. Will regulatory changes slow down biosimilar market entry?
   Potentially, if new requirements or patent disputes arise, delaying biosimilar availability and affecting price competition.

---

Sources

1. Transparency Market Research. Global oncology market report 2023.